Nevirapine or Lamivudine plus Stavudine and Indinavir: Examples of 2‐Class versus 3‐Class Regimens for the Treatment of Human Immunodeficiency Virus Type 1

Open Access

1 November 2002

journal article
clinical trial
Published by Oxford University Press (OUP) in Clinical Infectious Diseases

Vol. 35 (9) , 1096-1105
https://doi.org/10.1086/342694

Abstract

We compared use of a 3-class regimen (nevirapine [Nvp], stavudine [d4T], and indinavir [Idv; 1000 mg 3 times daily]) with use of a 2-class regimen (l

Keywords

This publication has 31 references indexed in Scilit:

Nelfinavir, Efavirenz, or Both after the Failure of Nucleoside Treatment of HIV Infection
New England Journal of Medicine, 2001
Genotypic and Phenotypic Resistance Patterns of Human Immunodeficiency Virus Type 1 Variants with Insertions or Deletions in the Reverse Transcriptase (RT): Multicenter Study of Patients Treated with RT Inhibitors
Antimicrobial Agents and Chemotherapy, 2001
Performance of a Quadruple Combination Including Nelfinavir Plus Efavirenz in Naive Subjects With High Baseline Viral Load and in Patients Failing Protease Inhibitor-Containing Regimens
JAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
Mechanisms of Virologic Failure in Previously Untreated HIV-Infected Patients From a Trial of Induction-Maintenance Therapy
JAMA, 2000
Antiviral Effect and Pharmacokinetic Interaction between Nevirapine and Indinavir in Persons Infected with Human Immunodeficiency Virus Type 1
The Journal of Infectious Diseases, 1999
A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected Patients
JAMA, 1998
High‐Dose Nevirapine in Previously Untreated Human Immunodeficiency Virus Type 1‐Infected Persons Does Not Result in Sustained Suppression of Viral Replication
The Journal of Infectious Diseases, 1997
Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter
New England Journal of Medicine, 1995
Determination of L-735 524, an human immunodeficiency virus protease inhibitor, in human plasma and urine via high-performance liquid chromatography with column switching
Journal of Chromatography A, 1995
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Proceedings of the National Academy of Sciences, 1993